Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of GLPG1837 in cystic fibrosis patients with S1251N mutation
2015-003292-30Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GLPG1837 in cystic fibrosis (CF) (2 arms), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability of GLPG1837. Started Nov 2015; status: completed.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-003292-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003292-30.